vs
Side-by-side financial comparison of Taysha Gene Therapies, Inc. (TSHA) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $5.0M, roughly 1.1× cbdMD, Inc.). cbdMD, Inc. runs the higher net margin — -5.6% vs -507.8%, a 502.1% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -1.9%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 7.1%).
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
TSHA vs YCBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.5M | $5.0M |
| Net Profit | $-27.9M | $-283.1K |
| Gross Margin | — | 59.8% |
| Operating Margin | -516.0% | -5.7% |
| Net Margin | -507.8% | -5.6% |
| Revenue YoY | 171.3% | -1.9% |
| Net Profit YoY | -48.3% | -1975.7% |
| EPS (diluted) | $-0.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.5M | $5.0M | ||
| Q3 25 | $0 | $4.7M | ||
| Q2 25 | $2.0M | $4.6M | ||
| Q1 25 | $2.3M | $4.7M | ||
| Q4 24 | $2.0M | $5.1M | ||
| Q3 24 | $1.8M | $4.6M | ||
| Q2 24 | $1.1M | $5.2M | ||
| Q1 24 | $3.4M | $4.4M |
| Q4 25 | $-27.9M | $-283.1K | ||
| Q3 25 | $-32.7M | $-680.0K | ||
| Q2 25 | $-26.9M | $-895.3K | ||
| Q1 25 | $-21.5M | $-480.8K | ||
| Q4 24 | $-18.8M | $15.1K | ||
| Q3 24 | $-25.5M | $-152.8K | ||
| Q2 24 | $-20.9M | $459.7K | ||
| Q1 24 | $-24.1M | $-3.0M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | 58.8% | ||
| Q2 25 | — | 61.5% | ||
| Q1 25 | — | 62.3% | ||
| Q4 24 | — | 66.5% | ||
| Q3 24 | — | 53.9% | ||
| Q2 24 | — | 65.8% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | -516.0% | -5.7% | ||
| Q3 25 | — | -14.5% | ||
| Q2 25 | -1347.1% | -19.6% | ||
| Q1 25 | -930.5% | -10.2% | ||
| Q4 24 | -985.8% | -1.7% | ||
| Q3 24 | -1448.4% | -6.9% | ||
| Q2 24 | -1915.4% | -7.4% | ||
| Q1 24 | -713.3% | -35.4% |
| Q4 25 | -507.8% | -5.6% | ||
| Q3 25 | — | -14.4% | ||
| Q2 25 | -1353.6% | -19.4% | ||
| Q1 25 | -935.2% | -10.1% | ||
| Q4 24 | -929.0% | 0.3% | ||
| Q3 24 | -1427.5% | -3.4% | ||
| Q2 24 | -1882.0% | 8.9% | ||
| Q1 24 | -705.4% | -68.8% |
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.08 | — | ||
| Q4 24 | $-0.07 | — | ||
| Q3 24 | $-0.10 | — | ||
| Q2 24 | $-0.09 | $-0.15 | ||
| Q1 24 | $-0.10 | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $319.8M | $3.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.9M | $9.0M |
| Total Assets | $343.3M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $319.8M | $3.4M | ||
| Q3 25 | $297.3M | $2.3M | ||
| Q2 25 | $312.8M | $1.1M | ||
| Q1 25 | $116.6M | $1.8M | ||
| Q4 24 | $139.0M | $2.0M | ||
| Q3 24 | $157.7M | $2.5M | ||
| Q2 24 | $172.7M | $2.4M | ||
| Q1 24 | $124.0M | $2.1M |
| Q4 25 | $246.9M | $9.0M | ||
| Q3 25 | $219.0M | $7.2M | ||
| Q2 25 | $248.7M | $6.1M | ||
| Q1 25 | $55.1M | $665.8K | ||
| Q4 24 | $71.5M | $1.8M | ||
| Q3 24 | $88.8M | $2.0M | ||
| Q2 24 | $108.9M | $3.0M | ||
| Q1 24 | $53.8M | $3.1M |
| Q4 25 | $343.3M | $11.8M | ||
| Q3 25 | $316.6M | $10.4M | ||
| Q2 25 | $333.3M | $9.9M | ||
| Q1 25 | $138.4M | $10.9M | ||
| Q4 24 | $160.4M | $11.5M | ||
| Q3 24 | $180.2M | $10.6M | ||
| Q2 24 | $200.4M | $13.8M | ||
| Q1 24 | $153.0M | $14.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.7M | $-812.5K |
| Free Cash FlowOCF − Capex | — | $-977.3K |
| FCF MarginFCF / Revenue | — | -19.5% |
| Capex IntensityCapex / Revenue | — | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.7M | $-812.5K | ||
| Q3 25 | $-24.2M | $-240.7K | ||
| Q2 25 | $-20.2M | $-704.2K | ||
| Q1 25 | $-22.0M | $-189.5K | ||
| Q4 24 | $-18.3M | $-317.9K | ||
| Q3 24 | $-21.6M | $167.4K | ||
| Q2 24 | $-21.5M | $289.8K | ||
| Q1 24 | $-19.8M | $-704.1K |
| Q4 25 | — | $-977.3K | ||
| Q3 25 | $-24.3M | $-243.6K | ||
| Q2 25 | — | $-705.7K | ||
| Q1 25 | — | $-205.0K | ||
| Q4 24 | $-18.3M | $-482.3K | ||
| Q3 24 | $-21.6M | $157.4K | ||
| Q2 24 | $-21.7M | — | ||
| Q1 24 | $-19.9M | $-708.7K |
| Q4 25 | — | -19.5% | ||
| Q3 25 | — | -5.2% | ||
| Q2 25 | — | -15.3% | ||
| Q1 25 | — | -4.3% | ||
| Q4 24 | -905.5% | -9.4% | ||
| Q3 24 | -1210.9% | 3.5% | ||
| Q2 24 | -1951.9% | — | ||
| Q1 24 | -584.5% | -16.2% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | 0.1% | 3.2% | ||
| Q3 24 | 2.0% | 0.2% | ||
| Q2 24 | 18.1% | 0.0% | ||
| Q1 24 | 4.1% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -21.06× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TSHA
Segment breakdown not available.
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
